SONATA raises $7M to pair your genome with a doctor

Key Takeaways

• SONATA raised $7M from Lux Capital, BoxGroup, and Sunflower Capital to launch in NYC, SF, and LA
• The $2,500 annual membership includes whole-genome sequencing, 140+ blood biomarkers, and DNA methylation analysis
• The company targets a gap between PDF-only genetic testing and $25K+ concierge medicine

SONATA closed a $7M seed round to launch a preventive healthcare membership that pairs clinical-grade genetic testing with ongoing physician care. The company, now emerging from stealth, will begin serving members in New York, San Francisco, and Los Angeles at $2,500 per year.

Lux Capital led the round, with BoxGroup, Sunflower Capital, and operators from Ramp and Linear participating. CEO Sagan Schultz, a physician who spent nearly a decade working in NYC restaurants before entering medicine, built SONATA around a frustration: healthcare waits for disease instead of preventing it.

What does a $2,500 membership actually include?

Members receive whole-genome sequencing, 140+ blood biomarkers, and DNA methylation analysis to measure biological age. That data feeds into SONATA's in-house clinical AI, which surfaces patterns across genetics, labs, medical history, and wearable data. A board-certified physician interprets everything and builds a personalized health plan.

The key difference from direct-to-consumer genetic tests like 23andMe or consumer wellness panels: the physician relationship persists. SONATA doctors adjust care plans as a member's health, goals, and biology change. The company positions this as catching risks that routine primary care rarely tests for, including polygenic disease predispositions and early metabolic dysfunction.

The $5 trillion problem SONATA wants to solve

Americans spend nearly $5 trillion annually on healthcare, more than any other country, yet life expectancy fell from 78.8 years in 2019 to 76.4 years in 2023. Chronic disease rates keep climbing. About 60% of American adults live with at least one chronic condition, and roughly 90% of healthcare spending goes toward managing these diseases after they appear.

Consumer health data has exploded through wearables, genetic tests, and biomarker panels. But without a physician to interpret and act on that information, most of it sits unused. "People have more health data than ever, but almost none of it turns into actual care," Schultz said. "That's the gap we built SONATA to close."

The founding team sees a structural problem: wellness products optimize for engagement metrics, while healthcare should optimize for outcomes. Schultz draws a line between the two. "A lot of what's called preventive health today is really a wellness product, testing packaged with content. We built SONATA as healthcare."

How SONATA compares to existing options

SONATA sits in a gap. On one side: data-only services like Function Health, which offers 100+ biomarkers for $499/year but no physician relationship. On the other: traditional concierge medicine practices charging $25,000 or more annually, often without the genetic testing component.

Forward, another preventive care startup that has raised over $225 million, operates membership clinics with in-house diagnostic equipment. Parsley Health offers functional medicine with a membership model. Neither emphasizes whole-genome sequencing as a core offering the way SONATA does.

The $2,500 price point is a bet that a meaningful segment of health-conscious professionals will pay premium rates for this combination, but won't pay concierge rates. Schultz describes early members as people in their 30s and 40s "who are thinking differently about their health," often triggered by starting families, noticing their own physical decline, or watching parents manage chronic disease.

The investor thesis

Lux Capital, known for backing deep-tech and science-driven companies, led the round. The fund's portfolio includes other healthcare plays like Recursion Pharmaceuticals and Resilience. BoxGroup has backed early-stage consumer and enterprise companies including Plaid, Warby Parker, and Airtable.

The investor mix signals a bet on both the clinical infrastructure (Lux) and the consumer membership model (BoxGroup). Having Ramp and Linear operators on the cap table suggests SONATA is also building for a founder and tech-worker demographic that values health optimization.

What SONATA still needs to prove

The hard question for any preventive healthcare company is proving outcomes. It's straightforward to measure whether someone's biomarkers improved. It's much harder to prove that a disease was prevented. The timeline for demonstrating reduced chronic disease rates stretches years or decades.

SONATA will also need to scale physician capacity without diluting the relationship-driven model. Concierge practices typically cap patient panels at a few hundred per doctor. If SONATA grows beyond early adopters, maintaining that depth becomes operationally complex.

Frequently Asked Questions

What is SONATA's preventive healthcare membership?

SONATA offers a $2,500/year membership that includes whole-genome sequencing, 140+ blood biomarkers, DNA methylation analysis, and ongoing care from a board-certified physician who creates and adjusts a personalized health plan.

How much did SONATA raise and from whom?

SONATA raised $7M in seed funding from Lux Capital, BoxGroup, Sunflower Capital, and operators from companies including Ramp and Linear.

Where is SONATA available?

SONATA is launching in New York, San Francisco, and Los Angeles.

How does SONATA differ from 23andMe or other genetic testing services?

Unlike direct-to-consumer tests that deliver a report without clinical context, SONATA pairs testing with a board-certified physician who interprets results and manages ongoing care, adjusting plans as health and biology change.

Who is SONATA's target customer?

SONATA targets health-conscious professionals in their 30s and 40s who want proactive care but don't want to pay $25,000+ for traditional concierge medicine.

Source: AlleyWatch